SEATTLE--(EON: Enhanced Online News)--October 7, 2013 – Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Tuesday, November 12, 2013, at 9:00 a.m. EST to review third quarter financial results.
Access to the discussion may be obtained as follows:
|Time:||9:00 a.m. EST / 6:00 a.m. PST|
|Date:||November 12, 2013|
|Dial-in:||1-877-548-9590 (domestic) or +1-720-545-0037 (international);|
|conference pass code: 74649983|
www.dendreon.com (homepage and investor relations section)
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-800-585-8367 or +1-404-537-3406 for international callers; the conference ID number is 74649983. The replay will be available from 12:00 p.m. EST on Tuesday, November 12, until 11:59 p.m. EST on Monday, November 18. In addition, the webcast will be archived for on-demand listening for 90 days at www.dendreon.com.
Dendreon Corporation also announced that management will present at the following conferences:
- Credit Suisse 2013 Healthcare Conference in Scottsdale, AZ, on November 13 at 3:00 p.m. MST
- Lazard Capital Markets 10th Annual Healthcare Conference in New York City on November 20 at 8:30 a.m. EST
The presentation will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.